Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2014

View Archived Issues

Protein-modified red blood cells engineered to deliver systemic payloads

Takeda Pharmaceutical reviews highlights of first quarter of fiscal 2014

Genetic modification of T-cell epitopes in therapeutic toxins to minimize immunogenic reactions

Valneva signs cell-line license agreement with GeoVax

Alvogen adds to Asian assets with acquisition of Dream Pharma

Mesoblast to collaborate with NIH on trial for stem cell therapy in heart failure

Cara Therapeutics initiates phase II trial of CR-845 in uremic pruritus

New Amsterdam Sciences studying NAS-911 as a co-therapeutic for influenza

Yabao Pharmaceuticals and Changzhou Le Sun Pharmaceuticals to develop oncology drug

New antisense oligonucleotides patented by Japanese group

Palobiofarma designs novel PDE10A inhibitors

Novo Nordisk offers overview of second quarter 2014

Leica Biosystems and Bristol-Myers Squibb collaborate on companion diagnostics

Novel agents for HCV infection disclosed by Bristol-Myers Squibb

Clinuvel declines Retrophin proposal

Novartis divulges novel Mdm2 and Mdm4 interaction inhibitors

OPKO Health submits IND for Rayaldee as an adjunctive cancer therapy

Trillium Therapeutics expands CD47 program into solid tumors

Chinese and U.S. researchers disclose novel antibacterial marinopyrrole derivatives

Oxygen Biotherapeutics confirms collaboration with Imperial College London

Baxter opens biologics facility with plans for expansion

FDA approves Invokamet for type 2 diabetes

Reversible non-peptide proteasome inhibitors as potential anticancer agents

Eylea approved in E.U. for DME

Daiichi Sankyo and Charleston Laboratories develop fixed-dose combination hydrocodone products

FDA approves Velcade for retreatment of multiple myeloma

Genentech files for U.S. approval of Lucentis for diabetic retinopathy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...